Recently my group has undertaken very broad cancer genome characterization studies, which require close collaboration with scientists from the sequencing facility, the microarray lab, the pathology and tissue groups, the diagnostics team, and other programmers and computational biologists. Cancer genomics has been our long-lasting interests. Next generation sequencing technologies provide unprecedented opportunities to reveal mysteries hidden in the complex mutational landscape of cancer. One aspect of our current work is to use emerging technologies such as the Complete Genomics platform to perform whole genome sequencing of cancer samples. Using the short-read sequence data, we are in the process of characterizing a wide variety of genetic alterations including point mutations and structural variations. In combination with other data types such as expression microarrays, SNP arrays, and Illumina-based RNA-Seq, we are studying how new insights from whole genome information can help us understand cancer biology and drug response. Another complementary aspect of our current work is the use of computational methods to predict the functional consequence of a given genetic lesion. This has been an active research area in my group, and I expect we will continue to leverage our expertise in this domain to distinguish driver from passenger mutations in cancer genomes.